No sex difference in HIV patients with boosted Reyataz

A retrospective study, which included 1,294 antiretroviral (ARV)-experienced patients, demonstrated no difference in time to virologic failure in women compared to men taking Reyataz (atazanavir sulphate), from BMS, (ATV/ritonavir)-based regimens, over a follow-up period of up to five years. The results revealed no gender-based differences in time to virological failure, defined as two consecutive HIV RNA = 50 c/mL or one HIV RNA = 50 c/mL followed by discontinuation. After three years of follow-up, the probability of not having virological failure was 59% for women (95% CI 52-65%) and 63% for men (95% CI 59-67%). As seen in several other recent studies, female gender was associated with increased risk of treatment discontinuation but not with a significantly higher risk of virologic failure.